# Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

> **NCT06173284** · PHASE3 · COMPLETED · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 519 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** 611
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT06173284
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-22
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-11-20
- **Target enrollment:** 519 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173284, "Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06173284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*